Drug Type Prophylactic vaccine |
Synonyms Influenza A virus vaccine H5N1(Novartis Pharma AG), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) + [1] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (28 Nov 2010), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
influenza A subtype H5N1 infection | European Union | 28 Nov 2010 | |
influenza A subtype H5N1 infection | Iceland | 28 Nov 2010 | |
influenza A subtype H5N1 infection | Liechtenstein | 28 Nov 2010 | |
influenza A subtype H5N1 infection | Norway | 28 Nov 2010 | |
Influenza in Birds | European Union | 28 Nov 2010 | |
Influenza in Birds | Iceland | 28 Nov 2010 | |
Influenza in Birds | Liechtenstein | 28 Nov 2010 | |
Influenza in Birds | Norway | 28 Nov 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza A virus infection | Phase 2 | United Kingdom | 01 Nov 2008 | |
Influenza, Human | Phase 1 | United Kingdom | 01 Jan 2009 |